Immunocore
IMCR
41 hedge funds and large institutions have $598M invested in Immunocore in 2021 Q1 according to their latest regulatory filings, with 41 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
34.04% more ownership
Funds ownership: 0% → 34.04% (+34%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$112M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$102M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$63.3M |
| 4 |
RI
RTW Investments
New York
|
+$55.5M |
| 5 |
BlackRock
New York
|
+$48.1M |
Top Sellers
IMCR Hedge Fund Activity: Q1 2021 in Review
41 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Immunocore (IMCR) for Q1 2021, worth a combined $598M.
Buyers outnumbered sellers: 41 funds opened new IMCR positions and 0 closed out — a net gain of 41 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $112M.
- 41 institutional investors held Immunocore (IMCR) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $598M of Immunocore stock for Q1 2021.
- 41 funds opened new Immunocore positions in Q1 2021 and 0 closed out, a net change of +41 holders.
- The largest Immunocore buyer in Q1 2021 was Baker Bros. Advisors, an estimated $112M added.
Based on aggregated 13F filings for Q1 2021.